AbbVie Inc. is a research-based biopharmaceutical company that researches, develops, manufactures, commercializes, and sells medicines and therapies worldwide. Its products include Skyrizi for autoimmune diseases, Rinvoq for inflammatory diseases, Imbruvica and Venclexta for blood cancers, Elahere for various cancers, Epkinly for lymphoma, and Emrelis for lung cancer. The company also offers facial injectables, body contouring, and skincare products, including Botox Cosmetic, Juvederm Collection, and Botox Therapeutic, as well as treatments such as Vraylar, Duodopa, Ubrelvy, Qulipta, and Vyalev. Additional products include eye care treatments like Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, and Refresh/Optive, and therapies such as Mavyret, Creon, and Linzess/Constella. AbbVie was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Unveils New VRAYLAR Real-World and Pediatric Safety Data at Psych Congress 2026
AbbVie shared new real-world and pediatric safety data for VRAYLAR in major depressive disorder and bipolar I at Psych Congress 2026. The findings covered routine clinical practice settings, including patients with complex comorbidities and underserved groups, while the pediatric data added information on safety and use in younger patients with mood disorders. AbbVie, a research-focused biopharmaceutical group with a US$466.6b market cap, positions VRAYLAR within a broad portfolio targeting chronic conditions including complex psychiatric disorders. The company said the next concrete checkpoint will be how these data feed into prescribing and label use over the next year, particularly uptake of newly approved low dose VRAYLAR in pediatric and adjunctive MDD settings, trackable in reported prescription trends and segment sales through 2027.
AbbVie Inc. has declared another quarterly dividend of $1.73 per share, payable November 16, 2026, to shareholders of record as of October 15, holding the payout steady throughout 2026 after raising it from $1.64 earlier in the year. The $1.73 quarterly payment works out to $6.92 per share annually and a yield of roughly 2.7%, a moderate level that AbbVie has not raised again this year. The company's dividend growth record is the larger story: the quarterly payout has climbed from $1.41 in 2022 to $1.48 in 2023, $1.55 in 2024, $1.64 in 2025 and $1.73 in 2026, a roughly 23% increase over that span, and AbbVie has raised its quarterly dividend by more than 330% since it was established in 2013, with the latest increase at 5.5%. In its latest SEC filing, AbbVie reported $7.27 billion in operating cash flow for the first six months of 2026, up from $6.79 billion a year earlier, while paying $6.2 billion in cash dividends during the same period, and it spent about $1.1 billion on acquisitions and investments and another $1.1 billion on share repurchases in that half. AbbVie said future dividends remain subject to board approval and cited its financial condition, capital requirements and debt obligations as factors.
AbbVie to Present Phase 3 Etentamig Results at 2026 IMS Meeting
AbbVie announced that full results from the Phase 3 CERVINO study of its investigational drug etentamig will be featured in a plenary presentation at the 23rd International Myeloma Society Annual Meeting, held September 23-26, 2026, in Glasgow, Scotland. Topline results showed that etentamig, a second-generation BCMA x CD3 bispecific T-cell engager, met the study's dual primary endpoints of objective response rate and progression-free survival versus standard available therapies in adults with triple-class exposed relapsed/refractory multiple myeloma. Beyond CERVINO, AbbVie will present research spanning its myeloma pipeline, including ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager, and surzetoclax, a BCL-2 small-molecule inhibitor, alongside studies of etentamig across multiple treatment settings. Additional presentations will cover treatment sequencing, infection-related healthcare utilization and costs, and real-world outcomes. Etentamig, ABBV-2001 (ISB 2001) and surzetoclax are investigational medicines and are not approved by any health authorities worldwide.
Allergan Aesthetics Reports Skin Quality Gains in Medical Weight Loss Patients
Allergan Aesthetics, an AbbVie company, announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combination with DiamondGlow dermabrasion treatments in individuals taking medical weight loss medications, including glucagon-like peptide-1 receptor agonists. The studies, presented at the Science of Skin Summit in Austin, Texas, from Sept. 17-20, 2026, showed statistically significant, investigator-assessed improvements in selected skin quality measures across the face, neck, upper inner arms and distal thighs. The 12-week skincare study included nine participants who completed the study, while the six-week DiamondGlow plus skincare study included 11 participants who completed at least one post-treatment assessment. In the 12-week study, participants reported that facial skin appeared approximately 10 years younger after four weeks of twice-daily growth factor serum use, and in the six-week study, participants reported facial skin appeared approximately 7.5 years younger after three DiamondGlow treatments and six weeks of the topical skincare regimen. Elizabeth Makino, a co-author of both studies and director of clinical development and global scientific affairs for skincare research and development at Allergan Aesthetics, said the early data contribute clinical evidence evaluating these approaches and that additional research in larger populations will help further characterize the findings.
AbbVie Raises 2026 Neuroscience Outlook to $12.7 Billion on Broad-Based Growth
AbbVie has raised its full-year 2026 neuroscience revenue outlook to approximately $12.7 billion, $100 million above its previous forecast, after the franchise generated $6.1 billion in first-half 2026 revenues, up 21.8% year over year on an operational basis. The growth was broad-based across the portfolio's three pillars of psychiatry, migraine and Parkinson's disease. Vraylar, the cornerstone of the psychiatry franchise, generated $1.98 billion in the first half, up 18.6%, and is now expected to approach $4.1 billion in full-year sales, while Botox Therapeutic brought in $2.05 billion and is expected to reach nearly $4.2 billion. In migraine, Ubrelvy generated $731 million and Qulipta $646 million, with Qulipta leading growth at 39.2% and Ubrelvy at 26.4%. The Parkinson's therapy Vyalev generated $457 million in first-half sales, with second-quarter sales up more than 27% sequentially, and AbbVie said it is well on track to achieve blockbuster sales this year. AbbVie also raised its overall 2026 revenue outlook by $300 million to approximately $67.6 billion, and expects an FDA decision on tavapadon, a once-daily oral Parkinson's therapy, in the third quarter of 2026, with management projecting more than $5 billion in peak sales across its three Parkinson's therapies.
Zelgen Pharmaceuticals and AbbVie Reach Strategic Partnership; First-Half Revenue Hits 1.205 Billion Yuan with First-Ever Half-Year Profit
Zelgen Pharmaceuticals Executive Vice President and Chief Scientific Officer Lyu Binhua revealed that the company has entered into a strategic partnership with multinational pharmaceutical company AbbVie regarding overseas licensing of its products. Lyu made the remarks while appearing on the first episode of the third season of the program "Hardcore Players in the Shanghai Market," themed "Innovative Drugs Crossing the Value Inflection Point." In 2025, Zelgen Pharmaceuticals reported revenue of 810 million yuan, up 52 percent year on year. In the first half of 2026, the company's revenue reached 1.205 billion yuan, achieving its first-ever half-year profit.
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Trial
AbbVie Inc. said its migraine treatment atogepant, sold as Qulipta in the U.S., met the main goal of a late-stage study evaluating its ability to prevent migraines associated with the menstrual period. Patients taking the drug experienced an average of 0.8 fewer migraine days than those receiving placebo over three menstrual cycles, with the treatment taken for seven consecutive days around the expected start of menstruation. Because atogepant is already approved in the U.S. for migraine prevention, the new data could potentially support an additional indication without requiring AbbVie to establish an entirely new drug franchise. The company may still need to show a meaningful advantage for menstrual migraine patients, since the benefit was modest and competition remains intense from rivals including Eli Lilly and Pfizer. The new indication could also have a limited incremental revenue impact, as menstrual migraine represents a narrower patient population than the broader migraine-prevention market.
Bristol Myers' arlo-cel hits main goal in mid-stage multiple myeloma trial
Bristol-Myers Squibb Company said its experimental CAR-T cell therapy arlocabtagene autoleucel, or arlo-cel, met the main goal of a mid-stage trial in patients with advanced multiple myeloma who had already gone through four major classes of standard treatments, producing a statistically significant and clinically meaningful improvement in overall response rates. The therapy also met a key secondary goal, with some patients achieving complete elimination of detectable cancer, and Bristol Myers said the safety profile was in line with what would be expected from CAR-T and other GPRC5D-targeting therapies. The company has not yet released the detailed numbers and plans to present the full results at an upcoming medical conference. Arlo-cel works by modifying a patient's own immune cells so they can target GPRC5D on cancer cells, and the results strengthen Bristol Myers' position in the competitive multiple myeloma market, where Reuters cites roughly 36,000 new U.S. cases expected this year. Competition remains intense, with recent results from AbbVie showing strong potential for its experimental treatment etentamig in relapsed or refractory multiple myeloma, and investors still need the detailed clinical data before judging how strong and durable the benefits really are.
AbbVie Declares $1.73 Quarterly Dividend, In Line With Previous
AbbVie declared a quarterly dividend of $1.73 per share, unchanged from its prior payout. The forward yield comes to 2.74%. The dividend is payable Nov. 16 to shareholders of record as of Oct. 15, which is also the ex-dividend date.
AbbVie's Qulipta Hits Phase 3 Goal in Menstrual Migraine
AbbVie said its migraine drug Qulipta achieved the main goal of a Phase 3 trial targeting menstrual migraine, sending shares up about 0.4% to $252.25 Thursday morning. The trial tested a sharper, more targeted dosing schedule, giving patients atogepant for seven straight days starting three days before menstruation across three cycles. Qulipta reduced perimenstrual migraine days by 0.8 versus placebo while also improving headache burden, rescue-medication use, disability and cognitive symptoms. Commercially, Qulipta delivered $350 million in second-quarter revenue, rising 30.9% and accounting for roughly 10.8% of AbbVie's $3.23 billion neuroscience portfolio. The $252.25 share price stands 14.55% above the $220.20 GF Value estimate, and detailed safety results, regulatory approval and insurer coverage still separate positive data from new revenue.
AbbVie Immunology Sales Hit $16.1 Billion as Skyrizi and Rinvoq Offset Humira Erosion
AbbVie's immunology franchise generated $16.1 billion in first-half 2026 sales, more than half of the company's total sales, as Skyrizi and Rinvoq continued to offset the biosimilar erosion of Humira that began in the United States in 2023. The segment's sales rose nearly 16% year over year on a reported basis, outpacing AbbVie's overall revenue growth, and the company expects combined Skyrizi and Rinvoq sales to exceed $31 billion in 2026. Rinvoq was approved in the EU in July for vitiligo and alopecia areata, and AbbVie believes those two indications alone can add up to $2 billion in combined peak sales, while phase III data for Rinvoq in hidradenitis suppurativa and systemic lupus erythematosus are expected later this year. Supported by those two drugs, AbbVie expects high-single-digit compound annual revenue growth through 2029, with no major loss-of-exclusivity events expected to materially disrupt the business through the rest of the decade. Beyond its current leaders, AbbVie is evaluating Skyrizi-based combination regimens with ABBV-382 and ABBV-701 in inflammatory bowel disease, seeking approval for a subcutaneous induction regimen of Skyrizi in Crohn's disease, and has added pipeline assets through acquisitions including Nimble Therapeutics, Capstan Therapeutics and Apogee Therapeutics, whose zumilokibart is a phase III-ready long-acting anti-IL-13 antibody for atopic dermatitis that AbbVie believes can compete with Dupixent.
AbbVie Inc. finalized its acquisition of clinical-stage biotech Apogee Therapeutics for $135.11 per share in cash, a $10.9 billion deal that folds Apogee's inflammatory and immunology pipeline into AbbVie's commercial engine. On the same day, AbbVie reported positive Phase 3 results for its bispecific T-cell engager etentamig in relapsed/refractory multiple myeloma, highlighting the company's push into next-generation immunology and oncology. In Q2 2026, AbbVie posted $16.99 billion in net revenue, up 10.2% year over year, with adjusted diluted EPS rising 22.9% to $3.65, driven by immunology blockbusters Skyrizi and Rinvoq, which grew 24.4% and 24.5% respectively, offsetting a 35.9% decline in Humira revenue. AbbVie reiterated its full-year 2026 adjusted EPS guidance of $13.87–$14.07, including a $0.14 dilutive impact from the Apogee transaction. Apogee, which generated no product revenue in Q2 2026, reported a net loss of $85.9 million but held $1.3 billion in cash and marketable securities, plus a $1.3 billion non-dilutive credit collaboration with Blackstone Life Sciences to support Phase 3 trials of its lead asset zumilokibart. Investors should watch full plenary data for etentamig at the International Myeloma Society Meeting from September 23–26 and monitor Phase 3 execution for zumilokibart under AbbVie's global structure.
AbbVie's Etentamig Meets Goals in Phase III Myeloma Study
AbbVie announced positive top-line results from the Phase III CERVINO study, in which its investigational drug etentamig significantly improved objective response rate and progression-free survival compared with standard therapies in patients with relapsed or refractory multiple myeloma who had been exposed to three major drug classes. The study met both primary goals, with etentamig achieving an objective response rate of 74% versus 45.7% for standard available therapies, and reducing the risk of disease progression or death by 60%, corresponding to a progression-free survival hazard ratio of 0.40. At 12 months, the overall survival rate was 87.9% for etentamig-treated patients versus 72% for those on standard therapies, though the prespecified statistical boundary for overall survival was not crossed at the data cutoff. The drug also showed a manageable safety profile with low rates of cytokine release syndrome and fatal infections. AbbVie plans to discuss the results with regulatory authorities and present the data at a medical conference later this month. Separately, AbbVie completed its acquisition of Apogee Therapeutics for approximately $10.9 billion, strengthening its immunology pipeline with dermatology, respiratory, and inflammatory disease assets.
SkinMedica Launches Barrier Calming Cream and Hydra Collagen Facial Mist
Allergan Aesthetics, an AbbVie company, has expanded its SkinMedica portfolio with the launch of Barrier Calming Cream, a restorative moisturizer designed to soothe skin and fortify the skin barrier, alongside the new HA5 Hydra Collagen Facial Mist with Vegan Collagen. In clinical testing, the cream improved skin barrier support and reduced skin dryness by 30% after just two weeks, while the mist immediately increased skin hydration by 31% with one application and improved dryness by 62%. The products are priced at $140 and $58 respectively and are available at SkinMedica.com and through licensed physicians and medically supervised spas. Nicole Mowad-Nassar, president of Global Allergan Aesthetics, highlighted the brand's pioneering role in regenerative skincare, and Prithwiraj Maitra, vice president of global skincare R&D, noted the cream's clinically proven ability to restore the barrier and support retinol tolerance.
Josh Brown Picks Incyte and Biogen as Top Healthcare Stocks
Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte and Biogen as two of his top stock picks, saying he wanted to take a break from the AI capital expenditure theme. Brown praised Biogen for its strong fundamentals and earnings, but the focus here is on Incyte, which is up 22% this year. Incyte, which develops drugs for blood cancers and inflammatory skin diseases, reported a 38% rise in revenue and a 40% jump in net product sales in its latest quarter, beating estimates. Its key product Jakafi saw sales rise 7%, while Opzelura sales increased 24%. The company raised its full-year fiscal 2026 sales guidance by about 7% and lifted the Opzelura outlook by roughly 40%, and it expects about 10 clinical data readouts in the second half of fiscal 2026. Risks include Jakafi's potential loss of exclusivity in 2028 and competition from AbbVie's Rinvoq, which recently won European approval for vitiligo.
J&J's China Pill Approval Challenges Its Own Injection Franchise
Johnson & Johnson won Chinese approval for its once-daily oral psoriasis treatment Icotyde, a pill that could compete with its own injectable drug Tremfya. The approval targets a market of more than 8.4 million people in China with moderate-to-severe plaque psoriasis, though local pricing, launch timing, and sales guidance remain undisclosed. Icotyde blocks the IL-23 receptor and was supported by a Phase 3 program of roughly 2,500 patients, which also underpinned its earlier U.S. approval. The convenience of a pill may attract patients who avoid injections, but converting Tremfya users would merely shift revenue within J&J, so real growth depends on untreated patients or taking share from rivals like AbbVie and Bristol Myers Squibb. At $266.59, the stock trades 38.32% above its GF Value estimate of $192.73, leaving little room for a soft launch.
AbbVie Files for EU Approval of Subcutaneous Skyrizi in Crohn's Disease
AbbVie has submitted a regulatory application to the European Medicines Agency seeking approval for its blockbuster immunology drug Skyrizi (risankizumab) as a subcutaneous induction treatment for adults with moderately to severely active Crohn's disease. If approved, EU patients would gain an additional subcutaneous induction option alongside the currently approved intravenous regimen, followed by maintenance dosing every eight weeks. The filing is based on data from the phase III AFFIRM study, which evaluated the drug's safety and efficacy in this patient population, including those with and without prior advanced therapy failure. AbbVie is also awaiting a U.S. regulatory decision on the same regimen, expected in the fall, which could improve convenience and competitive positioning. Skyrizi sales rose 26.3% year over year to nearly $10 billion in the first half of 2026, accounting for about 31% of AbbVie's total revenues, though the company faces pricing headwinds and competition from J&J's new oral pill Icotyde and Eli Lilly's Omvoh.
U.S. pharmaceutical giant Johnson & Johnson (J&J) announced on the 27th that Chinese drug regulators have approved its oral psoriasis treatment Icotide. China has more than 8.4 million psoriasis patients, and in this market, J&J's Tremfya, Bristol-Myers Squibb's Sotyktu, and AbbVie's Skyrizi are among the competitors. Analysts point out that Icotide, as a once-daily oral medication, could become a blockbuster and take market share from injectables. Icotide is approved for the treatment of moderate to severe plaque psoriasis, and Chinese companies such as InnoCare Pharma and Takeda are also developing oral treatments.
AbbVie Oncology Sales Dip 2.4% as Imbruvica Declines
AbbVie's oncology revenues fell 2.4% year over year to $1.65 billion in the second quarter of 2026, pressured by a 29.4% drop in Imbruvica sales to $532 million. The decline was attributed to competitive pressure and IRA-driven pricing changes. Growth in other oncology products partially offset the decline, with Venclexta sales up nearly 10% to $771 million, Elahere up 32% to $211 million, and Epkinly up 48% to $103 million. The quarter also marked the launch of Decnupaz, AbbVie's first marketed ADC in hematology, following FDA approval for BPDCN. AbbVie shares have gained 16% year to date, underperforming the industry's 18% growth, and the stock trades at 17.15 times forward earnings, below the industry average of 19.44.
AbbVie Reports New Lung Cancer Data at World Conference
AbbVie presented new clinical, translational and real-world data from its lung cancer portfolio at the World Conference on Lung Cancer in August 2026, including high objective response rates and generally manageable safety profiles for investigational therapies ABBV-1480 and ABBV-706, plus progress on Temab-A trials in non-small cell lung cancer. The breadth of these lung cancer programs, spanning bispecific antibodies and antibody-drug conjugates across first-line and relapsed settings, underscores how oncology innovation is becoming a more important pillar alongside AbbVie's existing immunology and neuroscience franchises. The company's narrative projects $81.5 billion revenue and $24.6 billion earnings by 2029, requiring 8.2% yearly revenue growth and about an $18.3 billion earnings increase from $6.3 billion today. Simply Wall St community members have only three fair value estimates for AbbVie, ranging from about US$273 to US$455 per share, showing very different expectations.
Spyre's SPY772 HS Study Could Broaden Growth Beyond IBD
Spyre Therapeutics expanded its inflammatory-disease strategy in August with SPY772 and the phase II SKYLIGHT study in hidradenitis suppurativa, or HS, moving its combination approach into a new disease area beyond inflammatory bowel disease and rheumatology. SKYLIGHT is evaluating SPY072 plus bimekizumab against bimekizumab alone in approximately 150 adults with moderate-to-severe HS, with the primary endpoint of HiSCR75 response rate at week 16 and topline data expected in late 2027 or early 2028. The study tests whether adding SPY072 to bimekizumab can improve the week-16 response rate relative to bimekizumab alone, and positive results could support further SPY772 development in HS and other indications. Spyre's pipeline already spans ulcerative colitis, rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis, and the company is advancing multiple IBD monotherapies and dual-antibody combinations. Competition in HS includes AbbVie's established Humira and its developing ABBV-1451, as well as Incyte's FDA-accepted New Drug Application for povorcitinib with a U.S. launch targeted for the first quarter of 2027 if approved. Research and development expenses rose 63.2% year over year to $65.5 million in the second quarter of 2026, and Spyre ended the quarter with $1.15 billion in cash, cash equivalents and marketable securities, which management expects to fund operations into the second half of 2029.
Johnson & Johnson's pipeline is becoming an increasingly important growth driver as the company looks to offset future pressure from mature products such as Stelara and eventually Darzalex. The company has a particularly strong set of catalysts in oncology, immunology and neuroscience, with several potential approvals, label expansions and important phase III readouts scheduled. In the past year, it has gained approval for new products like Inlexzo/TAR-200, a first-of-its-kind drug-releasing system, for treating high-risk non-muscle invasive bladder cancer, Imaavy (nipocalimab) for treating generalized myasthenia gravis and Icotyde (icotrokinra), an oral targeted peptide inhibitor of the IL-23 receptor, for treating moderate-to-severe plaque psoriasis. J&J markets Icotyde in partnership with Protagonist Therapeutics. On the second-quarter conference call, J&J said that it is seeing strong launches of Inlexzo, Icotyde, as well as Imaavy. Nipocalimab, an FcRn blocker, is also being evaluated for various immune-mediated conditions. It is under priority review in the United States for warm autoimmune hemolytic anemia, in late-stage studies for hemolytic disease of the fetus and newborn, systemic lupus erythematosus and Sjogren's disease, and in mid-stage studies for idiopathic inflammatory myopathy. J&J believes that nipocalimab has pipeline-in-a-product potential. J&J believes that Icotyde/icotrokinra has the potential to revolutionize the treatment of plaque psoriasis with a once-daily pill, whereas most currently available effective options for treating plaque psoriasis are injectables, such as AbbVie's popular injection, Skyrizi, and J&J's own injection, Tremfya. Icotyde offers a compelling advantage over existing plaque psoriasis treatments by combining biologic-level precision with the convenience of an oral pill. Unlike injectable IL-23 biologics, such as AbbVie's Skyrizi and Tremfya, it eliminates the need for injections, improving patient comfort and adherence. Icotrokinra is also being evaluated in phase III studies for ulcerative colitis and psoriatic arthritis and in phase II for Crohn's Disease. It has the potential to be J&J's largest product ever, with $10 billion in sales potential. J&J expects several meaningful pipeline catalysts in the second half of the year, including potential FDA regulatory approval for Imaavy for warm autoimmune hemolytic anemia. In July, J&J announced positive top-line data from the phase III MonumenTAL-6 study evaluating Tecvayli plus Talvey in patients with relapsed or refractory multiple myeloma who had received one to four prior lines of therapy. The combination regimen reduced the risk of disease progression or death by 89% versus investigator's choice of standard care while reducing the risk of death by 62%. Other important data readouts expected later this year include Inlexzo in high-risk bladder cancer, Icotyde in psoriatic arthritis and Caplyta in bipolar mania. A key pipeline candidate is JNJ-4804, a co-antibody therapeutic being developed in phase III studies for ulcerative colitis and Crohn's disease. The company is also working on expanding labels of currently marketed products like Darzalex, Tremfya, Carvykti, Erleada, Rybrevant/Lazcluze and others. As regards its MedTech segment, a key product approved recently in the United States was the OTTAVA robotic surgery system, J&J's next-generation soft-tissue surgical robot. It was approved in July. VARIPULSE Pro, an advanced Pulsed Field Ablation platform, is expected to be approved by the FDA later this year. VARIPULSE Pro was launched in the EU in April. Overall, J&J's robust pipeline and a steady stream of clinical and regulatory catalysts should support growth in the second half of 2026 and beyond. The potential expansion of newer drugs, strong late-stage candidates and continued MedTech innovation provide multiple avenues for J&J to offset patent pressures and sustain long-term growth. J&J's shares have outperformed the industry so far this year. The stock has risen 30.6% year to date compared with 18.2% appreciation of the industry. From a valuation standpoint, J&J is expensive. Going by the price/earnings ratio, the company's shares currently trade at 21.84 forward earnings, higher than 19.50 for the industry. The stock is also trading above its five-year mean of 15.65. The Zacks Consensus Estimate for 2026 earnings has risen from $11.58 per share to $11.59 per share over the past 60 days, while that for 2027 earnings has gone up from $12.65 per share to $12.80 over the same time frame. J&J has a Zacks Rank #3 (Hold) at present.
AbbVie's Q2 Revenue Rises 10.2% on Skyrizi and Rinvoq Growth
AbbVie reported fiscal Q2 2026 worldwide revenue of $16.99 billion, up 10.2%, driven by strong immunology and neuroscience growth. Skyrizi revenue increased 24.4% to $5.51 billion and Rinvoq rose 24.5% to $2.53 billion, together accounting for about 47% of total revenue, while Humira sales fell 35.9% to $756 million. Neuroscience revenue grew 20.3% to $3.23 billion, led by Vraylar, Botox Therapeutic, Qulipta, and Vyalev. Adjusted diluted EPS rose 22.9% to $3.65, but the company lowered its full-year adjusted EPS guidance to $13.87–$14.07, citing anticipated dilution from the proposed Apogee Therapeutics acquisition. Oncology revenue declined 1.5% to $1.65 billion and aesthetics grew only 0.3% on a reported basis, highlighting concentration risk in the two immunology products.
Rongchang Bio's first-half net profit attributable to parent reaches 4.66 billion yuan, turning from loss to profit year-on-year
Rongchang Bio released its 2026 interim report, with net profit attributable to the parent turning from a loss of 450 million yuan in the same period last year to a profit of 4.66 billion yuan. The company's first-half operating revenue was 5.85 billion yuan, up 433.1 percent year-on-year; non-GAAP net profit attributable to the parent was 4.34 billion yuan, compared with a loss of 446 million yuan in the same period last year; net operating cash flow was 4.214 billion yuan, up 1,816.2 percent year-on-year. Second-quarter operating revenue was 5.2 billion yuan, up 808.6 percent year-on-year, and net profit attributable to the parent was 4.33 billion yuan. The company said sales revenue from its core products telitacicept and disitamab vedotin continued to grow, while the exclusive license agreement for RC148 signed with AbbVie brought substantial technology licensing revenue.
AbbVie Presents New Lung Cancer Clinical Data at WCLC 2026
AbbVie presented new clinical data at the 2026 World Conference on Lung Cancer covering several lung cancer programs across its pipeline. The update included efficacy and safety readouts for investigational therapies ABBV-1480, telisotuzumab adizutecan, and ABBV-706 in non-small cell and small cell lung cancer. The company outlined an expanded set of ongoing lung cancer trials that it stated could reshape its future oncology portfolio and longer-term growth profile. AbbVie has a market value of about $470.0 billion.
Billionaire hedge fund manager Ken Griffin's Citadel increased its position in AbbVie by 547% through the purchase of an additional 2.68 million shares at an average price of $214.90 per share. AbbVie, a Dividend King with 53 consecutive years of dividend increases, currently trades around $260 per share and yields about 2.8%. The company is spending $10.9 billion to acquire Apogee Therapeutics, gaining the potential atopic dermatitis therapy Zumilokibart, which offers a three- to six-month dosing schedule versus two to three weeks for Dupixent. AbbVie spent $13.8 billion on research and development in 2025 and has more than 90 candidate compounds in clinical development, including 375 clinical-stage programs. The deal is not expected to increase adjusted earnings per share until 2032.
AbbVie Raises Neuroscience Sales Guidance to $12.7 Billion for 2026
AbbVie now expects its neuroscience portfolio to generate approximately $12.7 billion in revenue during 2026, raising guidance by another $100 million after a strong first half of the year. The portfolio generated $10.8 billion last year and continues to grow at a double-digit pace. Second-quarter neuroscience revenue climbed 20.3% year over year to $3.23 billion, led by Vraylar at $1.07 billion, therapeutic Botox at $1.04 billion, and migraine drugs Ubrelvy and Qulipta at $742 million combined. AbbVie also acquired Gilgamesh Pharmaceuticals' lead drug candidate bretisilocin for $906 million upfront, with another $300 million tied to future development milestones, as part of its push into psychedelics-based medicines for major depressive disorder.
Genmab and AbbVie Confirm Epcoritamab Trial Missed Survival Endpoint
Genmab and AbbVie confirmed that the Phase 3 EPCORE DLBCL-1 study of epcoritamab failed to meet its primary endpoint of overall survival in the United States. The trial evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed or refractory diffuse large B-cell lymphoma. While the drug maintains its accelerated FDA approval, the companies must review the full data set with regulators to determine a path forward. Genmab reported first-half 2026 revenue of $2.051 billion, up 25% year over year, and raised its full-year revenue guidance to $4.325 billion to $4.525 billion. AbbVie posted second-quarter net revenues of $16.99 billion, up 10.2%, with adjusted diluted EPS of $3.65, up 22.9%.
AbbVie reported first-quarter 2026 worldwide net revenues of $15.002 billion, up 12.4% on a reported basis, and raised its full-year adjusted diluted EPS guidance to $14.08–$14.28. The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which beat internal expectations despite a $0.41 per share unfavorable impact from acquired IPR&D and milestone expenses. Separately, Allergan Aesthetics announced European Commission approval of Boey, the first rapid-onset, short-duration botulinum neurotoxin serotype E in Europe, across all 30 European Economic Area countries. Canaccord raised its price target on AbbVie to $282 from $273 while maintaining a Buy rating, citing expected strength in core prescription volumes and recent developmental wins. Hedge fund data tracked by Insider Monkey showed 87 funds held AbbVie positions in Q1 2026, up from 84 in Q4 2025.
RemeGen discloses 2026 interim results forecast with revenue expected to surge 433 percent, swinging to profit
RemeGen has disclosed its 2026 interim results forecast, expecting first-half operating revenue of approximately 5.85 billion yuan, an increase of about 4.75205 billion yuan compared with the same period in 2025, representing year-on-year growth of roughly 433 percent. The company expects net profit attributable to owners of the parent of about 4.7 billion yuan for the first half, swinging to a profit; net profit after deducting non-recurring items is expected to be about 4.3 billion yuan, also swinging to a profit. The significant change in performance is mainly due to continued growth in domestic sales revenue of its core products telitacicept and disitamab vedotin, as well as substantial technology licensing revenue from an exclusive license agreement for RC148 signed with a holding company of AbbVie. The financial data in this forecast are only preliminary estimates and have not yet been audited by certified public accountants.
AbbVie Wins Canada Reimbursement Backing for Adult Migraine Treatment
AbbVie received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision follows Phase 3 trial results and a review process that included direct input from patients and clinicians. The recommendation expands access to UBRELVY in Canada and broadens AbbVie's neuroscience portfolio in migraine care.
AbbVie Gains as FDA Accepts Botox Filing for New Indication
AbbVie's Allergan Aesthetics unit reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in adults, a potential fifth U.S. aesthetic indication. AbbVie shares have risen to $247.97, with a 90-day return of 19.3% and a one-year total shareholder return of 28.71%. A widely followed fair value estimate places the stock at about $273 per share, implying a 9.3% discount, though the stock trades at a P/E of 69.9x compared with 16.8x for the broader U.S. biotech industry.
AbbVie's Skyrizi and Rinvoq drove over 47% of total revenue in Q2 2026
AbbVie reported second-quarter 2026 results that beat earnings and sales expectations, with immunology drugs Skyrizi and Rinvoq together accounting for more than 47% of total revenues. Skyrizi sales rose 24% operationally to $5.5 billion and Rinvoq sales rose 23.7% to more than $2.5 billion, driven by strong demand and market-share gains across approved indications, especially in inflammatory bowel disease. The company raised its full-year Skyrizi sales forecast by $100 million to approximately $21.7 billion and expects combined Skyrizi and Rinvoq growth of more than 20% in 2026. Rinvoq received EU approval for vitiligo and alopecia areata, with U.S. decisions expected later this year and in early 2027, and AbbVie anticipates nearly $2 billion in combined peak sales from these two dermatology indications. Legacy drug Humira saw sales decline 36.1% to $756 million due to biosimilar competition, but the immunology franchise continues to offset that erosion.
AbbVie Takes On $8 Billion in Debt to Fund Apogee Therapeutics Acquisition
AbbVie is taking on $8 billion in debt to finance its $10.6 billion acquisition of Apogee Therapeutics, a deal expected to close in the third quarter pending regulatory approvals. The company said the acquisition will not boost adjusted earnings per share until 2032 and will cause $0.14 in dilution this year, lowering its adjusted EPS guidance to a range of $13.87 to $14.07. AbbVie plans to maintain its dividend, having raised it by 5.5% to $1.73 per share this year, and aims to preserve its A2/A- credit rating while reducing net leverage to about 2 times within two to three years after closing. The deal is centered on Apogee's lead drug candidate, Zumilokibart, a monoclonal antibody targeting interleukin-13 for atopic dermatitis with a three- to six-month dosing interval that could compete with Sanofi's Dupixent, which generated 15.7 billion euros in 2025 sales. AbbVie reported second-quarter revenue of $16.9 billion, up 10.2%, and earnings per share of $2.03, a 290% increase from the prior year.
FDA accepts AbbVie's Botox Cosmetic application for masseter muscle prominence
The FDA accepted for review a supplemental Biologics License Application for AbbVie's Botox Cosmetic to treat masseter muscle prominence, a jaw-muscle bulge that can widen the face. If approved, Botox Cosmetic would become the first and only neurotoxin cleared for that use in the US and the fifth aesthetic indication for the drug. The filing is supported by two Phase 3 studies that met their primary endpoints with statistically significant improvements versus placebo. AbbVie's broader business reported net revenue of just under $17 billion in the latest quarter, up more than 10% year over year, driven by immunology and neuroscience growth.
AbbVie lowered its full-year adjusted EPS guidance to $13.97 at the midpoint, a 1.5% decrease, even as second-quarter revenue rose 10.2% year-on-year to $16.99 billion, beating analyst estimates of $16.79 billion. Adjusted EPS of $3.65 also exceeded the $3.61 consensus. CEO Robert Michael highlighted over 20% growth in both the immunology and neuroscience portfolios, with SKYRIZI achieving market leadership in multiple countries. During the earnings call, analysts pressed management on SKYRIZI's subcutaneous induction timeline, competitive dynamics in psoriasis, and the Tevapadon launch in Parkinson's disease, while executives expressed confidence in pipeline progress and manufacturing readiness.
Ironwood Pharmaceuticals reported adjusted earnings of 31 cents per share for the second quarter of 2026, beating the Zacks Consensus Estimate of 26 cents. Total revenues were $113 million, missing the estimate of $120 million but surging 32.6% year over year. The company raised its full-year 2026 revenue guidance to a range of $460 to $485 million, up from the prior $450 to $475 million, driven by higher demand for Linzess. U.S. sales of Linzess, recorded by partner AbbVie, are now expected to be between $1.15 billion and $1.20 billion, compared with the earlier projection of $1.13 billion to $1.18 billion. Ironwood also lifted its adjusted EBITDA outlook to more than $310 million from more than $300 million.
Nxera Pharma swings to net profit of JPY 1,591 million in first half of FY2026
Nxera Pharma reported a net profit of JPY 1,591 million (US$10.1 million) for the six months ended 30 June 2026, reversing a net loss of JPY 3,137 million (US$21.1 million) in the prior corresponding period. Revenue totalled JPY 18,910 million (US$119.6 million), an increase of JPY 3,815 million (US$18.0 million) versus the prior corresponding period, driven by eight R&D milestone events in the current quarter compared with five a year earlier. Operating profit reached JPY 1,881 million (US$11.9 million) against an operating loss of JPY 2,756 million (US$18.5 million), while core operating profit surged to JPY 6,494 million (US$41.1 million) from JPY 364 million (US$2.5 million). The company highlighted progress across partnered programs, including milestone payments from Neurocrine Biosciences, AbbVie, and Centessa Pharmaceuticals, and noted that Lilly's acquisition of Centessa does not affect Nxera's rights to future milestone and royalty payments from the jointly created orexin receptor agonist pipeline.
REGENXBIO on track for RGX-202 BLA submission in Q3 2026 with over $310 million pro forma cash
REGENXBIO reported second quarter 2026 financial results and reaffirmed its timeline for a Biologics License Application submission for RGX-202 in Duchenne muscular dystrophy in the third quarter of 2026, with potential accelerated approval in the second half of 2027. The company received over $200 million in new capital in July 2026, including a $100 million milestone payment from AbbVie for dosing the first patient in the Phase IIb/III NAAVIGATE diabetic retinopathy study and approximately $108 million in net proceeds from an underwritten public offering, extending its cash runway into the fourth quarter of 2027. Pro forma cash, cash equivalents and marketable securities as of June 30, 2026 were in excess of $310 million. Topline data from the pivotal ATMOSPHERE and ASCENT trials of surabgene lomparvovec for wet AMD are expected in the fourth quarter of 2026, and the company plans to resubmit the BLA for RGX-121 in Hunter syndrome in the third quarter of 2026 following a positive Type A meeting with the FDA. Net income for the second quarter was $22.7 million, or $0.43 per share, compared to a net loss of $70.9 million in the prior-year period, driven primarily by the $100 million milestone from AbbVie.
AbbVie Keeps Raising Its Dividend and Wall Street Sees a 12% Upside
AbbVie continues to raise its dividend despite market headwinds, and Wall Street analysts see the stock climbing nearly 12% from current levels. The company posted second-quarter revenue of nearly $17 billion, a 10.2% year-over-year increase, while adjusted earnings per share rose 23% to $3.65. Its immunology drugs Skyrizi and Rinvoq are expected to generate $31 billion in combined sales this year, replacing former blockbuster Humira. AbbVie also announced the acquisition of Apogee Therapeutics for $10.9 billion in cash to bolster its pipeline with the eczema treatment zumilokibart. The drugmaker is a Dividend King with 54 consecutive years of payout increases, including its time as part of Abbott Laboratories.
USA